|
Dec 22
|
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
|
|
Dec 22
|
Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approval
|
|
Dec 21
|
An Intrinsic Calculation For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Suggests It's 42% Undervalued
|
|
Dec 9
|
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
|
|
Dec 6
|
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?
|
|
Dec 1
|
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
|
|
Nov 29
|
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a Bet
|
|
Nov 28
|
When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit?
|
|
Nov 27
|
11 Best Upside Stocks To Buy Right Now
|
|
Nov 8
|
1 Gene Therapy Stock to Buy and Hold for the Long Haul
|
|
Nov 8
|
Insider Spends US$3.9m Buying More Shares In Sarepta Therapeutics
|
|
Nov 8
|
Here’s What Bronte Capital Calls “Sarepta Risk” in the Context of Sarepta Therapeutics (SRPT)
|
|
Nov 2
|
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat
|
|
Nov 2
|
Sarepta Therapeutics to Present at the UBS Biopharma Conference
|
|
Sep 7
|
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
|
|
Aug 23
|
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
|
|
Aug 22
|
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
|
|
Jun 29
|
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
|
|
Jun 23
|
Sarepta Plummets Despite Winning FDA Nod For $3.2 Million Gene Therapy
|